SiNtx Technologies Inc (SINT)

[CL101]

Parallel example of LOI & milestone payment:

The Board of Onoclys BioPharma (“Oncolys”) is pleased to announce that it has resolved, at its board
meeting on the 20 May 2016, to execute a binding Letter-of-Intent (“LOI”) with Jiangsu Hengrui Medicine
Co., Ltd. (“Hengrui”) for oncolytic virus OBP-301 (Telomelysin®) license in China, to pave the way for an
exclusive license agreement between the two companies.
Hengrui is a top-tier pharmaceutical company in China known for its integrated business operations
which cover the entire process related to pharmaceutical businesses, from research and development,
commercialization, manufacturing and distribution of drugs. In China, in particular, it is also known as a
pharma specialized in oncology with more than 40% of its revenue from oncology-related drugs, keeping a
top share in the Chinese market for the past 10 years in a row. One of the greatest strengths Hengrui has
is its R&D forces extending across the world including in the US and Europe, diversification of products
and comprehensive product lines. It is a remarkable achievement in fact that Hengrui independently
developed a novel anti-VEGFR-2 agent named Apatinib, the world’s first small molecule anti-angiogenesis
targeting agent to treat late gastric cancer, which was approved and launched in 2014. Furthermore, in
2015, Hengrui entered into a global license and collaboration agreement with a Nasdaq-listed US
biopharma Incyte Corporation for the development and commercialization of its investigational anti-PD-1
monoclonal antibody, SHR-1210, with the terms including potential milestone payments of approximately
$800 million.
Upon the conclusion of this LOI, both companies foresee to enter into an exclusive license agreement for
Telomelysin® in China, by the end of November 2016. A related impact on OBP’s earnings prediction for the
FY2016 shall be disclosed after the license agreement is successfully executed.

http://www.oncolys.com/en/pdf/news_20160520_1.pdf